Hypoxia inducible factor (HIF) pathway
Singh AK, et al.. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085−2098. doi: 10.1056/NEJMoa065485
Drüeke TB, et al.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071−2084. doi: 10.1056/NEJMoa062276
Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019−2032. doi: 10.1056/NEJMoa0907845
Macdougall IC. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol 2008; 3:200−207. doi: 10.2215/CJN.03840907
Macdougall IC. Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10:607−614. https://doi.org/10.1093/ndt/10.5.607
Regidor DL, et al.. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17:1181−1191. doi: 10.1681/ASN.2005090997
Wyatt CM, Drüeke TB. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Kidney Int 2016; 90:923−925. doi: 10.1016/j.kint.2016.08.016
Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol 2010; 298:F1287−F1296. doi: 10.1152/ajprenal.00736.2009
Haase VH. Oxygen sensors as therapeutic targets in kidney disease. Nephrol Ther 2017; 13 (Suppl 1):S29−S34. doi: 10.1016/j.nephro.2017.01.015
Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447−5454. doi: 10.1128/MCB.12.12.5447
Sugahara M, et al.. Hypoxia-inducible factor and oxygen biology in the kidney. Kidney360 2020; 1:1021−1031. doi: https://doi.org/10.34067/KID.0001302020
Li Z-L, et al.. Treatment of renal anemia with roxadustat: Advantages and achievement. Kidney Dis (Basel) 2020; 6:65−73. doi: 10.1159/000504850
Locatelli F, et al.. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017; 45:187−199. doi: 10.1159/000455166
Fishbane S, et al.. Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol [published online ahead of print February 10, 2021]. doi: 10.1681/ASN.2020081150; https://jasn.asnjournals.org/content/early/2021/02/09/ASN.2020081150
Chen N, et al.. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019; 381:1011−1022. doi: 10.1056/NEJMoa1901713
Chertow GM. Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD. ASN Kidney Week 2020 Reimagined. 2020; FR-OR54. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3479290
Eckardt K-U Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD. ASN Kidney Week 2020 Reimagined. 2020; TH-OR01. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3441404
Provenzano R, et al.. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep [published online ahead of print December 24, 2020]. doi: 10.1016/j.ekir.2020.12.018; https://www.sciencedirect.com/science/article/pii/S2468024920318519
Provenzano R, et al.. Pooled Efficacy and Cardiovascular (CV) Analyses of Roxadustat in the Treatment of Anemia in CKD Patients on and Not on Dialysis. ASN Kidney Week 2020 Reimagined. 2020; FR-OR131. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3275139
Kuriyama S, et al.. A new insight into the treatment of renal anemia with HIF stabilizer. Ren Replace Ther 2020; 6:63. doi: https://doi.org/10.1186/s41100-020-00311-x
Coyne DW, et al.. Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia. ASN Kidney Week 2020 Reimagined. 2020; TH-OR04. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3447031